Atamyo completes the dose-finding study in Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) and obtains US Rare Pediatric Disease Designation for ATA-100

Atamyo completes the dose-finding study in Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) and obtains US Rare Pediatric Disease Designation for ATA-100

Posted on By admin
Atamyo completes the dose-finding study in Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) and obtains US Rare Pediatric Disease Designation for ATA-100

admin

Learn More →

Related Posts

AskBio Inc. Advances Gene Therapy Clinical Trial for LGMD2I/R9 with Dosing of First Participant in Second Cohort

By adminPosted on Posted in News
Read More

Connecting for a Cure 2024

By adminPosted on Posted in News

Check out our Events page for fundraising event details and how you can support this year!

Read More